HC Wainwright Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) had its price target increased by equities research analysts at HC Wainwright from $40.00 to $48.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 132.16% from the stock's current price. HC Wainwright also issued estimates for Enliven Therapeutics' Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($2.14) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.59) EPS, Q3 2026 earnings at ($0.62) EPS, Q4 2026 earnings at ($0.65) EPS and FY2026 earnings at ($2.42) EPS.

ELVN has been the topic of a number of other reports. The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a research note on Monday, June 16th. They issued a "buy" rating and a $37.00 price target on the stock. Jones Trading cut their target price on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. Finally, Robert W. Baird boosted their target price on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a research note on Monday, June 16th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $41.20.

Enliven Therapeutics Price Performance

NASDAQ:ELVN traded up $0.04 during mid-day trading on Wednesday, reaching $20.68. The stock had a trading volume of 272,510 shares, compared to its average volume of 297,479. Enliven Therapeutics has a 12 month low of $13.30 and a 12 month high of $30.03. The stock has a market capitalization of $1.01 billion, a PE ratio of -10.77 and a beta of 0.83. The stock has a 50-day simple moving average of $19.58 and a two-hundred day simple moving average of $20.35.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). Equities analysts expect that Enliven Therapeutics will post -1.95 EPS for the current year.

Insider Buying and Selling at Enliven Therapeutics

In other news, CEO Samuel Kintz sold 12,500 shares of the stock in a transaction dated Tuesday, June 17th. The stock was sold at an average price of $22.18, for a total value of $277,250.00. Following the completion of the sale, the chief executive officer owned 952,892 shares of the company's stock, valued at approximately $21,135,144.56. This represents a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Joseph P. Lyssikatos sold 12,500 shares of the firm's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $21.40, for a total value of $267,500.00. Following the transaction, the insider owned 965,188 shares of the company's stock, valued at $20,655,023.20. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 100,111 shares of company stock worth $1,939,549. 25.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ELVN. Charles Schwab Investment Management Inc. lifted its stake in Enliven Therapeutics by 2.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 261,888 shares of the company's stock valued at $5,892,000 after buying an additional 6,611 shares during the period. Swiss National Bank increased its stake in shares of Enliven Therapeutics by 13.9% in the 4th quarter. Swiss National Bank now owns 41,873 shares of the company's stock valued at $942,000 after acquiring an additional 5,100 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Enliven Therapeutics during the 4th quarter valued at $367,000. KLP Kapitalforvaltning AS bought a new position in Enliven Therapeutics during the fourth quarter worth $97,000. Finally, Vanguard Group Inc. grew its holdings in Enliven Therapeutics by 2.9% in the fourth quarter. Vanguard Group Inc. now owns 1,975,655 shares of the company's stock worth $44,452,000 after purchasing an additional 55,283 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.